X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Neumifil’s active component, HEX17, is a multivalent, glycan-targeting carbohydrate binding module. It is being developed for the broad-spectrum anti-viral for those infections caused by influenza virus, respiratory syncytial virus, rhinovirus and coronavirus.
Lead Product(s): HEX17
Therapeutic Area: Infections and Infectious Diseases Product Name: Neumifil
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
The funding will advance the Phase 2 clinical development of Neumifil (sialic acid binding protein), a novel, engineered multivalent Carbohydrate Binding Molecule, for individuals with Chronic Obstructive Pulmonary Disease suffering from virus induced exacerbations.
Lead Product(s): Sialic Acid Binding Protein
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Neumifil
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Thairm Bio
Deal Size: $10 million Upfront Cash: Undisclosed
Deal Type: Financing June 01, 2023
Details:
Neumifil’s active component, HEX17, is a multivalent, glycan-targeting carbohydrate binding module. It is being developed for the broad-spectrum anti-viral for those infections caused by influenza virus, respiratory syncytial virus, rhinovirus and coronavirus.
Lead Product(s): Neumifil
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Neumifil is a novel intranasal spray designed to provide at-risk patients with an easy-to-use broad-spectrum antiviral treatment to reduce, prevent and manage underlying disease exacerbations caused by viral infections.
Lead Product(s): Neumifil
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
Top line data from the trial show that Neumifil is well tolerated with no dose limiting toxicities and a safety profile that strongly supports further development. No serious adverse events were reported at any of the doses evaluated in the study.
Lead Product(s): Neumifil
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Proceeds from the financing will support the clinical development and manufacturing of its lead product Neumifil. Neumifil is a unique multivalent carbohydrate binding molecule (mCBM) generated using Pneumagen’s proprietary GlycoTarge™ technology platform.
Lead Product(s): Neumifil
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Thairm Bio
Deal Size: $5.2 million Upfront Cash: Undisclosed
Deal Type: Financing January 19, 2022
Details:
The funding is directed towards the clinical development of Neumifil, a first-in-class Carbohydrate Binding Modules (mCBMs), generated using the Company’s proprietary GlycoTarge™ platform, for the prevention and treatment of COVID-19.
Lead Product(s): Carbohydrate binding modules
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Thairm Bio
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 27, 2020
Details:
Pneumagen's mCBMs were found to reduce the number of SARS-CoV-2 plaques when the mCBMs were used in both prevention and treatment of infection.
Lead Product(s): Carbohydrate binding modules
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Details:
Pneumagen has initiated a new programme to prevent and treat COVID-19 infections using its first-in-class Carbohydrate Binding Modules, generated using its proprietary GlycoTarge™ platform.
Lead Product(s): Carbohydrate binding modules
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
